June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
IV Push Administration for Outpatient Parenteral Antimicrobial Therapy
July 26th 2022Investigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.
Read More
Antibiotic Therapy Often Used Improperly in Kids with MIS-C Related to COVID-19
July 17th 2022Most children with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 receive improper antimicrobial treatment, according to a recent study that highlights an urgent need to improve diagnosis and treatment of the condition.
Read More
Challenging Gram Negative Pathogens and Oral Carbapenems: MAD-ID Updates With Jason Pogue, PharmD
May 21st 2022Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.
Watch
Antimicrobial Stewardship Pearls to Optimize Patient Outcomes: Matthew B. Goetz, MD
May 19th 2022“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.
Watch
The Underlying Threat of Multidrug-Resistant Pathogens in the COVID-19 Era
May 16th 2022Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.
Read More
Omadacycline: ‘A Modernized Tetracycline’
May 13th 2022Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.
Watch